MedTrace Logo

Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm

NCT00076817 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2012-10-29

No results posted yet for this study

Summary

The purpose of this study is to determine the safety of and immune system response to the ALVAC-HIV (vCP205) vaccine when it is injected either into the groin area or into the arm. The goal is to determine if injecting the vaccine into the groin area produces a better immune response in the lining of the rectum.

Conditions

  • HIV Infections
  • HIV Seronegativity

Interventions

BIOLOGICAL

ALVAC-HIV (vCP205)

Canarypox virus vector vaccine

BIOLOGICAL

ALVAC-HIV (vCP205)

Canarypox virus vector vaccine placbo

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Peter Anton, MD · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2007-09-30
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00076817 on ClinicalTrials.gov